Favorite  |  Set Home
Products > Others > > Atglistatin
Product name : Atglistatin
Item : CR1814
Price : 200mg, $945;500mg, $1485
contact : Send inquiry to: info@acesobio.com
Additional Information :  We offer significant discount for bulky quantity order,Please ask price and availability of other quantities
CAS : 1469924-27-3
 Enlarge Image                   Back
←[Previous Product]              [Next Product]→


Details:
 Chemical Information
M.Wt 283.37 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C17H21N3O
CAS No 1469924-27-3
Solubility

DMSO up to 100 mM



Biological Activity of Atglistatin

 

Atglistatin is a highly potent, selective and competitive inhibitor of adipose triglyceride lipase (ATGL) with an IC50 of ~0.7 μM for inhibition of lipolysis in vitro, but no toxicity up to a concentration of 50 μM.
IC50 value: 0.7 uM [1]
Target: ATGL
Atglistatin inactivated ATGL in the presence or absence of the ATGL co-activator CGI-58. It does not displace ATGL from lipid droplets of adipocytes. Immunoprecipitation experiments revealed that Atglistatin does not interfere with the interaction of ATGL and CGI-58. Atglistatin inhibited TG hydrolase activity of wild-type WAT in a dose-dependent manner up to 78% in animal models. It was highly effective in inhibiting lipolysis in WAT organ cultures of wild-type mice. Dose and time-dependent inhibition of lipolysis was also observed in fasted wild-type C57Bl/6J mice. Atglistatin can serve as a very useful tool compound to study the pathophysiology and druggability of ATGL in animal models of metabolic disease and cachexia [1].

 

[1]. Mayer N, et al. Development of small-molecule inhibitors targeting adipose triglyceride lipase. (2013) Nat Chem Biol. 9(12):785-7.
Abstract
Adipose triglyceride lipase (ATGL) is rate limiting in the mobilization of fatty acids from cellular triglyceride stores. This central role in lipolysis marks ATGL as an interesting pharmacological target as deregulated fatty acid metabolism is closely linked to dyslipidemic and metabolic disorders. Here we report on the development and characterization of a small-molecule inhibitor of ATGL. Atglistatin is selective for ATGL and reduces fatty acid mobilization in vitro and in vivo.


Related Products :
TPT-260
TPT-260
Price: 200mg, $945; 500mg, $1485
MS436
MS436
Price: 100mg, $945; 200mg, $1485
SC 26196
SC 26196
Price: 10mg, $295; 50mg, $795; 100mg, $1295; 200mg, $1995
DCG 04
DCG 04
Price: 10mg,$1295; 50mg,$3975; 100mg, $6795; 200mg, $9755
Montelukast (MEK 0476)
Montelukast (MEK 0476)
Price: 10mg, $125; 50mg, $395; 100mg, $595; 200mg, $995
PF-543
PF-543
Price: 100mg, $945; 200mg, $1485
Decitabine
Decitabine
Price: 10mg, $75, 50mg, $295; 100mg, $475; 200mg, $795
Prasugrel metabolite
Prasugrel metabolite
Price: 10mg, $295; 50mg, $795; 100mg, $1295; 200mg, $2295